Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Successful use of rasagiline in combination with two antidepressants: a case report.

Kaur N, Madan R, Sharma A.

Innov Clin Neurosci. 2012 Nov;9(11-12):39-41.

2.

The role of rasagiline in the treatment of Parkinson's disease.

Leegwater-Kim J, Bortan E.

Clin Interv Aging. 2010 May 25;5:149-56. Review.

3.
4.

Rasagiline - a novel MAO B inhibitor in Parkinson's disease therapy.

Lecht S, Haroutiunian S, Hoffman A, Lazarovici P.

Ther Clin Risk Manag. 2007 Jun;3(3):467-74.

5.

Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.

Guay DR.

Am J Geriatr Pharmacother. 2006 Dec;4(4):330-46. Review.

PMID:
17296539
6.

Adjunctive therapy in Parkinson's disease: the role of rasagiline.

Gaines KD, Hinson VK.

Neuropsychiatr Dis Treat. 2012;8:285-94. doi: 10.2147/NDT.S25142. Epub 2012 Jul 2.

7.

Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease.

Hoy SM, Keating GM.

Drugs. 2012 Mar 26;72(5):643-69. doi: 10.2165/11207560-000000000-00000. Review. Erratum in: Drugs. 2012 Apr 16;72(6):870-1.

PMID:
22439669
8.

Spotlight on rasagiline in Parkinson's disease.

Oldfield V, Keating GM, Perry CM.

CNS Drugs. 2008;22(1):83-6.

PMID:
18072817
9.

Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline.

deMarcaida JA, Schwid SR, White WB, Blindauer K, Fahn S, Kieburtz K, Stern M, Shoulson I; Parkinson Study Group TEMPO; PRESTO Tyramine Substudy Investigators and Coordinators.

Mov Disord. 2006 Oct;21(10):1716-21.

PMID:
16856145
10.

Rasagiline meta-analysis: a spotlight on clinical safety and adverse events when treating Parkinson's disease.

Solís-García del Pozo J, Mínguez-Mínguez S, de Groot PW, Jordán J.

Expert Opin Drug Saf. 2013 Jul;12(4):479-86. doi: 10.1517/14740338.2013.790956. Epub 2013 May 2.

PMID:
23634791
11.

Rasagiline: a review of its use in the management of Parkinson's disease.

Oldfield V, Keating GM, Perry CM.

Drugs. 2007;67(12):1725-47. Review.

PMID:
17683172
12.

Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease.

Chen JJ, Ly AV.

Am J Health Syst Pharm. 2006 May 15;63(10):915-28. Review.

PMID:
16675649
13.

Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects.

Schapira AH.

CNS Drugs. 2011 Dec 1;25(12):1061-71. doi: 10.2165/11596310-000000000-00000. Review.

PMID:
22133327
14.

Pharmacology of Rasagiline, a New MAO-B Inhibitor Drug for the Treatment of Parkinson's Disease with Neuroprotective Potential.

Finberg JP.

Rambam Maimonides Med J. 2010 Jul 2;1(1):e0003. doi: 10.5041/RMMJ.10003. Print 2010 Jul.

15.

Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa.

Rabey JM, Sagi I, Huberman M, Melamed E, Korczyn A, Giladi N, Inzelberg R, Djaldetti R, Klein C, Berecz G; Rasagiline Study Group.

Clin Neuropharmacol. 2000 Nov-Dec;23(6):324-30.

PMID:
11575866
16.

[Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].

Jost WH, Klasser M, Reichmann H.

Fortschr Neurol Psychiatr. 2008 Oct;76(10):594-9. doi: 10.1055/s-2008-1038249. Epub 2008 Oct 2. German.

PMID:
18833504
17.

MAO-inhibitors in Parkinson's Disease.

Riederer P, Laux G.

Exp Neurobiol. 2011 Mar;20(1):1-17. doi: 10.5607/en.2011.20.1.1. Epub 2011 Mar 31.

18.

The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge?

Chen JJ, Wilkinson JR.

J Clin Pharmacol. 2012 May;52(5):620-8. doi: 10.1177/0091270011406279. Epub 2011 May 31. Review.

PMID:
21628600
19.

Role of rasagiline in treating Parkinson's disease: Effect on disease progression.

Malaty IA, Fernandez HH.

Ther Clin Risk Manag. 2009 Aug;5(4):413-9. Epub 2009 Jun 4.

20.

Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study.

Masellis M, Collinson S, Freeman N, Tampakeras M, Levy J, Tchelet A, Eyal E, Berkovich E, Eliaz RE, Abler V, Grossman I, Fitzer-Attas C, Tiwari A, Hayden MR, Kennedy JL, Lang AE, Knight J; ADAGIO investigators.

Brain. 2016 Jul;139(Pt 7):2050-62. doi: 10.1093/brain/aww109. Epub 2016 May 13.

PMID:
27190009
Items per page

Supplemental Content

Write to the Help Desk